Thousands of sex offenders across England and Wales may soon have access to medication designed to suppress sexual arousal as part of their sentence or parole conditions. The approach, already in use in several countries, remains controversial among ethicists and medical professionals who question whether such treatment should ever be mandatory.
For some prisoners experiencing problematic sexual arousal (PSA), intrusive sexual imagery dominates their consciousness throughout waking hours. Prof Belinda Winder, a leading forensic psychologist who has studied the effectiveness of libido-suppressing medications, has documented cases where offenders report dramatic relief after beginning treatment.
"I remember talking to one guy a few weeks after he started taking the medication. He said: 'It's amazing. I followed a film plot. I wasn't just looking for when I could see bra straps, when I could see nipples, when someone's going to bend over so I could see their bum.'"
Winder explained that without medication, such intrusive thoughts consumed the offender's mental space continuously.
"Without the drugs, these images were going around his head all the time. He did not want them any more,"she said.
What medications are used in the UK?
Two main categories of drugs are employed to manage problematic sexual arousal in UK prisons and under parole supervision. Selective serotonin reuptake inhibitors (SSRIs) work by limiting invasive sexual thoughts through their antidepressant action, while anti-androgens reduce testosterone levels and suppress libido more directly. According to government guidance, these medications are typically administered as pills.
However, the treatments are not universally suitable. Offenders whose behaviour is primarily driven by anger rather than sexual arousal, or those who struggle to maintain abstinence from alcohol or drugs, may not be appropriate candidates. The government has emphasised that treatment works best when combined with coordinated psychological support rather than used in isolation.
How is chemical suppression used internationally?
Several European nations have implemented chemical suppression programmes, though with varying degrees of coercion. Denmark and France restrict the approach to voluntary participation only. Germany operates the Dunkelfeld project, which offers free and confidential therapies including medical interventions to men with paedophilic or hebephilic obsessions. An advertisement for the scheme features unidentified men stating:
"In therapy, I learned that no one is to blame for their sexual preference. But everyone is to blame for their behaviour. I don't want to be an offender."
Other jurisdictions have adopted mandatory approaches. Poland introduced compulsory chemical suppression for certain sex offenders. South Korea became the first Asian nation to legalise chemical castration in 2010, granting courts and a Ministry of Justice committee authority to order involuntary hormone treatment for convicted sex offenders to suppress testosterone.
In Australia, several states empower courts and parole boards to mandate anti-libidinal treatment for high-risk offenders as a condition of release. Kazakhstan and multiple US states including California and Florida already require anti-libidinal drug prescribing for certain sex offenders.
What is the UK government's position?
UK officials have investigated whether participation in chemical suppression programmes could become a mandatory condition of parole licences, modelled on schemes operating in California. In September 2025, the government announced that approximately 6,400 sex offenders would be able to access chemical suppressants alongside psychological treatment, with the programme expanding from a pilot to more prisons. The planned expansion covers 20 prisons across England, including facilities in the north-west and north-east regions, with treatment remaining voluntary at that stage.
However, significant ethical questions persist about whether parole decisions should hinge on medication compliance. In May 2025, the Justice Secretary was reported to be considering whether chemical castration should become mandatory, though no timeline for such a policy change has been established.
What are the ethical concerns?
The historical precedent for such treatments casts a long shadow over current proposals. During the 1950s, hormone treatments were administered to men convicted of offences related to homosexuality, ostensibly to allow them to avoid imprisonment. Computer scientist and codebreaker Alan Turing, convicted of "gross indecency" in 1952, accepted chemical castration to escape jail. He died by suicide two years later.
Beyond historical concerns, the physical side effects of anti-androgens can be severe and life-altering. Men undergoing such treatment report fatigue, hot flushes, muscle loss, mood changes, weight gain and diminished bone density. These effects raise fundamental questions about whether parole should be conditional on accepting such consequences.
Experts also acknowledge that medication alone is insufficient. The drugs do not constitute a cure and do not address the underlying behavioural patterns that led to offending. Some programmes report high dropout rates, and compliance cannot be guaranteed even when treatment is voluntary.
How should parole decisions be made?
Winder emphasised that individual assessment remains essential.
"It is never going to be so simple that a decision will be taken on whether to give someone parole based on whether they are taking their meds,"she stated.
"Parole Boards take such decisions by assessing many factors, including how receptive they are to staff and how they interact with their peers. It is really important that people are trained in understanding what it means if someone is taking this medication and how that might affect a person's behaviour."
Each offender must be evaluated on their individual circumstances by the Parole Board, considering their engagement with staff, peer relationships, and overall risk profile rather than medication status alone.
